CTOs on the Move

Aurinia Pharmaceuticals

www.auriniapharma.com

 
Aurinia is a global clinical stage biopharmaceutical company focused on developing and commercializing innovative products to treat identifiable patient populations that are suffering from serious diseases with a high unmet medical need. The company is headquartered in Victoria, BC and focuses its development efforts globally.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.auriniapharma.com
  • 500 W Office Center Drive Suite 400
    Fort Washington, PA USA 19034
  • Phone: 250.708.4272

Executives

Name Title Contact Details
Darin Wilson
Senior Director, Enterprise IT Profile

Funding

Aurinia Pharmaceuticals raised $28.75M on 12/29/2016
Aurinia Pharmaceuticals raised $173.1M on 03/20/2017
Aurinia Pharmaceuticals raised $191.7M on 12/12/2019

Similar Companies

Techne Corporation

Techne Corporation , incorporated in Minnesota in 1981, is a holding company which has two wholly-owned operating subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) located in Minneapolis, Minnesota and R&D Systems Europe Ltd. (RDSE) located in Abingdon, England. Over 95% of TECHNE's revenues are derived from products developed and manufactured in-house. R&D Systems is a specialty manufacturer of biological products. It has two operating divisions: Hematology and Biotechnology. The Hematology Division develops and manufactures hematology controls, which are used in hospitals and clinical laboratories to check the accuracy of blood analysis instruments. The Biotechnology Division develops and manufactures biotechnology products including purified proteins (cytokines) and antibodies that are sold primarily to the research market, and assay kits which are sold to the research and clinical diagnostic markets. RDSE sells and distributes Techne's biotechnology products in Europe.  

Front Range Biosciences

Front Range Biosciences enables a grower to reduce crop loss due to pathogens, quickly sex a plant, and develop new strains of plants that have the most valuable commercial properties.

Boundless Bio

Boundless Bio, a San Diego based company backed by ARCH Venture Partners, is discovering and developing novel cancer therapeutics based on the role of extrachromosomal DNA (ecDNA) in driving tumorigenesis, resistance and recurrence. When DNA in cancer cells comes off chromosomes, “extrachromosomal DNA (ecDNA),” it becomes unbound and unwound, thereby enabling numerous copies of cancer-causing genes, driving cancer cells to grow and allowing them to resist treatment. At Boundless Bio, we are counterattacking this ecDNA phenomenon with boundless innovation and boundless energy to develop powerful new cancer medicines that eliminate cancer cells’ ability to employ ecDNA to survive.

Folio Conversant

Folio Conversant is the premier provider of research services and biospecimen solutions. We offer an extensive array of quality biospecimens, particularly Human tissue and biofluids, supported by comprehensive laboratory and analytical services. Science does not stand still. Our goal is to become a key partner in supporting your team`s research and development in order to accelerate new diagnostic and therapeutic options for patients.

Viracta

Viracta is focused on advancing a proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr Virus, and will pursue opportunities to address other serious virus-associated disease.